PubMed Health⌕ Search

PubMed · 10220084

Status epilepticus: current concepts.

Abstract

Status epilepticus (SE) is a common pediatric emergency encountered in the prehospital situations and in the emergency administration of anticonvulsants, which will cause the seizures to cease. Although prognosis is primarily determined by the etiology, the duration of SE and therapy administered have unequivocal impact. If the seizures last longer than 1 hour, homeostatic mechanisms may start to fail. A dynamic multidisciplinary approach is essential in seizure management. The emergency physician has a unique responsibility to provide state-of-the art therapy and individualize the involvement of other services. The input of the pediatric intensive care physician is critical and assumes a major role if the patient fails to respond to first-line therapy. The treatment of refractory status epilepticus requires labor-intensive hemodynamic support and suppression of central nervous system, with either an anesthetic agent or a barbiturate. There is an urgent need to formulate guidelines for management of refractory status epilepticus.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Haafiz, N Kissoon. 1999. Status epilepticus: current concepts.. https://doi.org/10.1097/00006565-199904000-00012

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗